ArticleScientific reports2025
Antioxidant and anti-inflammatory effects of Equisetum arvense L. on acid-induced ulcerative colitis in rats.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Byakangelicol Alleviates Ischemic Brain Injury by Inhibiting Microglial Activation and Oxidative Stress.Molecular neurobiology · 2026Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Equisetum arvense L. (EAL) has a long history in traditional medicine for its ability to address various digestive and inflammatory conditions. Here, we aimed to evaluate the therapeutic potential of the EAL hydroalcoholic extract (HAEA) compared with the standard medications in a rat model of ulcerative colitis (UC) caused by acetic acid. Eighty-one male Sprague Dawley rats were acquired and randomly allocated into nine equal groups: healthy control group, negative control groups (receiving normal saline and carboxymethyl cellulose gel base), positive control groups (receiving asacol rectally and mesalazine orally), and test groups treated with different amounts of HAEA. At the end of the experiment (7 days), colonic injury was evaluated by macroscopic, biochemical, and stereological assessments. The effectiveness of HAEA on colonic tissue was proved by significantly decreasing the malondialdehyde (MDA) and interleukin-1β (IL-1β) concentrations as well as myeloperoxidase (MPO) activity and increasing the superoxide dismutase (SOD) activities and glutathione peroxidase (GPx) in comparison to negative control groups. Particularly, the HAEA gel 10% rectal enema was significantly effective in decreasing MDA and IL-1β, as well as increasing GPx and SOD activities in comparison to positive control groups (P < 0.05). According to the stereological evaluations, HAEA 600 mg/kg orally and gel 10% rectal enema-treated groups, as well as the positive control groups, had significantly higher epithelium, submucosa, and muscularis mucosa volume density in comparison to the negative control groups (P < 0.001). This study showed promising therapeutic effects in all HAEA-treated groups, particularly HAEA gel 10% rectal enema in the induced UC rat model compared to conventional treatments. Both in vivo and in vitro findings indicate that EAL has the potential to be used as an additive therapeutic strategy in UC patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.